Bicara Therapeutics (BCAX) EBIT (2023 - 2026)

Bicara Therapeutics has reported EBIT for 4 years, with the latest figure at -$60.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 44.16% year-over-year to -$60.2 million; the trailing twelve-month figure through Mar 2026 stood at -$174.1 million (down 59.98% YoY), and the FY2025 full-year result was -$155.6 million, down 88.87% from the prior year.
• EBIT for Q1 2026 stood at -$60.2 million, down from -$41.1 million in the prior quarter.
• The five-year high for EBIT was -$9.5 million in Q3 2023, with the low at -$60.2 million in Q1 2026.
• Historically, EBIT has averaged -$29.2 million across 4 years, with a median of -$26.6 million in 2024.
• Annual changes were most pronounced in 2025 — EBIT plunged 171.81% — and 2026, when it tumbled 44.16%.
• Bicara Therapeutics' EBIT stood at -$13.7 million in 2023, then tumbled by 94.62% to -$26.6 million in 2024, then sank by 54.38% to -$41.1 million in 2025, then plunged by 46.5% to -$60.2 million in 2026.
• The last three EBIT figures came in at -$60.2 million (Q1 2026), -$41.1 million (Q4 2025), and -$40.7 million (Q3 2025), per Business Quant data.